NewsEvents

Your Yourlocation: Home > Efficacy of tiotropium bromide(136310-93-5) in the treatment of stable stage of moderate to severe chronic obstructive pulmonary disease

To observe the clinical efficacy of inhaled tiotropium bromide(136310-93-5) in patients with moderate to severe chronic obstructive pulmonary disease (COPD). Methods: Forty-four patients with moderate to severe COPD were randomly divided into two groups. The treatment group (n = 22) was treated with tiotropium bromide and the control group (n = 22) was blank control group. To observe the change of lung function after 12 weeks of treatment, the St George'8 Respiratory Questionnaire (SGRQ) and so on. The changes of exercise tolerance were observed by 6-minute walking test (6MWT) and the number of patients who were followed up for 3 to 6 months. Results: The estimated values of FEV1, FVC, FVC, FEV1 / FVC and FEV1 in the treatment group were significantly higher than those in the control group (P <0.05), and the difference was statistically significant (P <0.05) (6MWT) increased in the treatment group, and the number of acute exacerbations in the treatment group was significantly lower than that in the control group (P <0.05). Conclusion: Inhalation of tiotropium bromide(136310-93-5) can improve lung function and exercise tolerance in patients with moderate to severe COPD, reduce the incidence of acute exacerbation, and the risk of adverse reactions is small.

To evaluate the efficacy and safety of tiotropium bromide(136310-93-5) in the treatment of chronic obstructive pulmonary disease (COPD). Methods: The bronchial dilatation and safety of tiotropium bromide (21 cases, 18μg, qd) and ipratropium bromide (23 cases, 40μg q 6 h) were observed in COPD patients by double-blind and double-dose randomized controlled method. (FEV1) and forced vital capacity (FVC) were significantly increased in the tiotropium group (P <0.001). At 2 and 2 h, the increase of FEV1 was higher than that of ipratropium bromide (P <0.01). At 2 and 4 weeks after treatment, the FEV1 trough of tiotropium group increased significantly (P <0.01), which was higher than that of ipratropium bromide group. There was no significant difference in the incidence of adverse drug reactions between the two groups. Conclusion: Tiotropium is an effective and safe bronchodilator in the treatment of COPD patients. The efficacy and usage of tiotropium bromide are better than that of ipratropium bromide.

Address:211#Zhengfeng Building,Huanbaokejiyuan, Gaoxinkaifaqu, Jinan,250100,China TEL:086-531-82375818 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved